CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 80.96% of retail investor accounts lose money when trading CFDs with this provider. You should consider whether you understand how CFDs work and whether you can afford to take the high risk of losing your money.
Open platformOpen platform

Devyser Q3 sales rise on portfolio expansion

By Reuters News


Overview

  • Sweden diagnostics kit maker's Q3 net sales rose 5.8% yr/yr despite distributor inventory drag

  • Adjusted EPS for Q3 improved to SEK 0.43 from a loss last year

  • Company broadened product portfolio and signed new agreements to support future growth


Outlook

  • Company expects distributor inventory adjustment to continue impacting sales in Q4 2026

  • Devyser anticipates sales to the distributor will gradually normalize from 2027

  • Company sees underlying demand as strong despite near-term sales headwinds


Result Drivers

  • DISTRIBUTOR INVENTORY - Co said sales growth was held back by continued inventory adjustment at its largest distributor

  • PRODUCT PORTFOLIO EXPANSION - Co launched new chimerism assay with Thermo Fisher and broadened product portfolio

  • REAGENT RENTAL AGREEMENT - Co signed first reagent rental agreement in collaboration with Illumina to expand access to NGS


Company press release:


Key Details

Metric

Beat/Miss

Actual

Consensus Estimate

Q3 Sales

SEK 59.70 mln

Q3 Adjusted EPS

SEK 0.43

Q3 Adjusted Free Cash Flow

SEK 22 mln

Q3 EBIT

SEK 7.10 mln


Analyst Coverage

  • The current average analyst rating on the shares is "strong buy" and the breakdown of recommendations is 2 "strong buy" or "buy", no "hold" and no "sell" or "strong sell"

  • The average consensus recommendation for the biotechnology & medical research peer group is "buy."

  • Wall Street's median 12-month price target for Devyser Diagnostics AB is SEK137.50, about 123.6% above its November 2 closing price of SEK61.50

  • The stock recently traded at 36 times the next 12-month earnings vs. a P/E of 48 three months ago


Reuters Recommended Reads

  • Nov 3 - Sweden's OssDsign Q3 net sales fall 5.4%, as expected

  • Nov 2 - Immunovia Q3 net sales surge on PancreaSure uptake

  • Nov 2 - Denmark medical devices maker Coloplast's Q4 revenue rises


For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.


(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)

Capital.com is an execution-only brokerage platform and the content provided on the Capital.com website is intended for informational purposes only and should not be regarded as an offer to sell or a solicitation of an offer to buy the products or securities to which it applies. No representation or warranty is given as to the accuracy or completeness of the information provided.

The information provided does not constitute investment advice nor take into account the individual financial circumstances or objectives of any investor. Any information that may be provided relating to past performance is not a reliable indicator of future results or performance.

To the extent permitted by law, in no event shall Capital.com (or any affiliate or employee) have any liability for any loss arising from the use of the information provided. Any person acting on the information does so entirely at their own risk.

Any information which could be construed as “investment research” has not been prepared in accordance with legal requirements designed to promote the independence of investment research and as such is considered to be a marketing communication.